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ttp://dx.doi.org/10.1016/j.ajpath.2012.09.004Poly(ADP-ribosyl)ation (PARylation) is a post-translational protein modification effected by enzymes
belonging to the poly(ADP-ribose) polymerase (PARP) superfamily, mainly by PARP-1. The key
acceptors of poly(ADP-ribose) include PARP-1 itself, histones, DNA repair proteins, and transcription
factors. Because many of these factors are involved in the regulation of myofibroblast differentiation,
we examined the role of PARylation on myofibroblast differentiation. Overexpression of PARP-1 with an
expression plasmid activated expression of the a-SMA gene (Acta2), a marker of myofibroblast
differentiation in lung fibroblasts. Suppression of PARP-1 activity or gene expression with PARP-1
inhibitors or siRNA, respectively, had the opposite effect on these cells. PARP-1edeficient cells also
had reduced a-SMA gene expression. DNA pyrosequencing identified hypermethylated regions of the
a-SMA gene in PARP-1edeficient cells, relative to wild-type cells. Interestingly, and of potential
relevance to human idiopathic pulmonary fibrosis, PARP activity in lung fibroblasts isolated from
idiopathic pulmonary fibrosis patients was significantly higher than that in cells isolated from control
subjects. Furthermore, PARP-1edeficient mice exhibited reduced pulmonary fibrosis in response to
bleomycin-induced lung injury, relative to wild-type controls. These results suggest that PARylation is
important for myofibroblast differentiation and the pathogenesis of pulmonary fibrosis. (Am J Pathol
2013, 182: 71e83; http://dx.doi.org/10.1016/j.ajpath.2012.09.004)Supported in part by NIH grants HL28737, HL31963, HL52285,
HL77297 (S.H.P.), and HL91775 (C.A.H. and S.H.P.). This work made use
of the University of Michigan’s Pathology Flow Cytometry Core Labora-
tory and Cell and Molecular Biology Core of the Michigan Diabetes
Research and Training Center, funded by the National Institute of Diabetes
and Digestive and Kidney Diseases (DK020572).Suitably activated ﬁbroblasts can give rise to a differentiated
phenotype characterized by induction of a-smooth muscle
actin (a-SMA), which is incorporated into stress ﬁbers and are
therefore aptly identiﬁed as myoﬁbroblasts.1e3 These differ-
entiated cells are known to play important roles in lung
development, carcinogenesis, wound healing, tissue repair,
and ﬁbrosis.1e6 Although the tissue ﬁbroblast is a well-
established precursor cell for the myoﬁbroblast, there is
evidence that other cell types could give rise to this differen-
tiated phenotype.7 The mechanism underlying genesis of the
myoﬁbroblast is incompletely understood, however, and it
appears to be quite complex, involving diverse signaling
pathways, transcription factors, and epigenetic proc-
esses.3,8e11 Given the important function of this cell in these
processes and in related diseases, a more complete under-
standing of myoﬁbroblast differentiation would be of value in
providing new insights into novel approaches of how to
regulate myoﬁbroblast genesis as a means of controlling these
processes and/or treatment of related diseases.stigative Pathology.
.Poly(ADP-ribosyl)ation (PARylation) is a post-translational
protein modiﬁcation catalyzed by enzymes belonging to the
poly(ADP-ribose) polymerase (PARP) superfamily, mainly by
PARP-1.12,13 PARP-1 uses NADþ as the ADP donor to
generate the long branching poly(ADP-ribose) polymer cova-
lently attached to glutamate or aspartate residues of suitable
acceptor proteins.14 The known key acceptors of poly(ADP-
ribose) include PARP-1 itself (automodiﬁcation), histones,
DNA repair proteins, and transcription factors.15,16 Inhibitionof
PARylation in oxidative stress-related pathologies such as
arthritis, colitis, diabetes, and shock has emerged as a very
effective anti-inﬂammatory intervention in animalmodels.17e22
Hu et alProtective effects of PARP inhibition or PARP-1 deﬁciency in
asthma models have also been observed.23e25 Treatment of
hamsters with the PARP inhibitor nicotinamide signiﬁcantly
decreased bleomycin-induced lung ﬁbrosis and PARP activi-
ties.26,27 Additionally, various studies have demonstrated
PARylation of Smad3,28,29 PPARg,30,31 and DNA methyl-
transferase 1 (Dnmt1),32 known regulators of myoﬁbroblast
differentiation.8,11,31 However, the precise role of PARP-1 in
the regulation of myoﬁbroblast differentiation has not been
determined.
In the present study, we investigated the role of PARP-1 in
the regulation of myoﬁbroblast differentiation and evaluated
its potential in vivo importance in a model of pulmonary
ﬁbrosis. PARP-1 activated myoﬁbroblast differentiation,
whereas its inhibition or deﬁciency had the opposite effect, as
determined by a-SMA expression. Further studies indicated
that PARP-1 suppressed DNA methylation in the a-SMA
gene (Acta2) and affected the binding of Smad3 to the Smad3
binding element in the a-SMA promoter. In addition, lung
ﬁbroblasts isolated from idiopathic pulmonary ﬁbrosis (IPF)
patients exhibited signiﬁcantly increased PARP-1 expression
and activity relative to lung ﬁbroblasts isolated from control
subjects. Immunostaining of the ﬁbroblastic foci of lung
tissue sections from IPF patients showed induced PARP-1
expression in a-SMAepositive cells. Finally, in vivo mice
deﬁcient in PARP-1 expression exhibited attenuated
pulmonary ﬁbrosis in response to bleomycin-induced injury.
These results suggest that PARP-1 plays an essential role in
the regulation of myoﬁbroblast differentiation, with conse-
quent effect on pulmonary ﬁbrosis.
Materials and Methods
Ethics
Use of human tissue and animal care were conducted in
accordance with the NIH guidelines for survival Rodent
Surgery, the Animal Welfare Act, the Public Health Service
Policy on Humane Care and Use of Laboratory Animals,
and the Guide for the Care and Use of Laboratory Animals,
7th edition (1996). The study was reviewed and approved
by the University of Michigan Institutional Biosafety
Committee and the University Committee on Use and Care
of Animals.
Animals and Cell Culture
Pathogen-free female Fischer 344 rats, C57/BL6 mice, and
PARP-1edeﬁcientmice (7 to8weeks old)wereused; ratswere
purchased from Charles River Breeding Laboratories (Wil-
mington, MA) and mice were from the Jackson Laboratory
(Bar Harbor, ME). Fibroblasts were isolated by enzymatic
digestion, as described previously,11 and were maintained in
Dulbecco’smodiﬁed Eagle’smedium (DMEM) supplemented
with 10% plasma-derived serum (Cocalico Biologicals,
Reamstown, PA), antibiotics, 1% ITS (insulin, transferrin,72selenium) (Sigma-Aldrich, St. Louis, MO), 5 ng/mL platelet-
derived growth factor (PDGF; R&D Systems, Minneapolis,
MN), and 10 ng/mL epidermal growth factor (EGF; R&D
Systems).11 The adherent cells were then trypsinized and
passaged at least three times before use, to ensure>99%purity.
Pulmonary ﬁbrosis was induced by the endotracheal
injection of bleomycin (Blenoxane; 1.5 U/kg; Mead Johnson,
Princeton, NJ) in sterile PBS for each mouse, as described
previously.33 The control group received the same volume
of sterile PBS only. For evaluation of the ﬁbrotic response,
animals were sacriﬁced and the lungs were removed for
extracting RNA, for ﬁbroblast isolation 7 days after bleo-
mycin treatment, and for hydroxyproline assay and Western
blot analysis 21 days after bleomycin treatment. For all other
experiments,ﬁbroblasts isolated from normal healthy animals
were used.
To evaluate the role of PARP-1 in human cells, ﬁve primary
cultured ﬁbroblast lines from IPF patients and ﬁve primary
cultured human lung ﬁbroblast lines from control subjects
were used. The control or normal cells were deﬁned as those
obtained from histologically normal lung tissue distal from
tumor margins of lung resections. All cells were established
from lungs removed at the time of transplantation or death and
maintained in high-glucose DMEM containing 10% fetal calf
serum between passages 6 and 10, as described previously.34
Cells from each individual donor were cultured separately
and were analyzed individually, without mixing. The diag-
nosis of IPF was supported by history, physical examination,
pulmonary function tests, andhigh-resolution chest computed-
tomography ﬁndings typical of IPF.34 All patients fulﬁlled the
criteria for the diagnosis of IPF as established by the American
Thoracic Society and the European Respiratory Society.
Diagnoses were conﬁrmed by microscopic analysis of lung
tissue, which demonstrated the characteristic morphological
ﬁndings of interstitial pneumonia.34 Use of human tissues was
approved by the Institutional Review Boards of the University
of Minnesota and of the University of Michigan.
TGF-b Treatment
Recombinant TGF-b1 (240-B-002; R&D Systems, Minne-
apolis, MN) was dissolved in sterile 4 mmol/L HCl con-
taining 1 mg/mL bovine serum albumin, aliquoted, and
stored at 80C until use. Cells were washed with 1 PBS
and incubated with 4 ng/mL TGF-b or the same amount of
the dissolving buffer in conditioned medium (Dulbecco’s
modiﬁed Eagle’s medium containing 0.5% plasma-derived
serum) for the indicated time.
Plasmids and Constructs
The rat 2880 to þ32 promoter region, previously ampli-
ﬁed by PCR, was cloned into promoterless pGL3-basic
vector to form the a-SMApro-Luc construct, in which
luciferase reporter gene expression was controlled by the
a-SMA gene promoter.8ajp.amjpathol.org - The American Journal of Pathology
PARP-1 Activates a-SMA Gene ExpressionThe rat PARP-1 cDNA constructs, the lentivirus-based
shRNA constructs speciﬁc for PARP1 gene, and the nega-
tive control shRNA construct were purchased from Thermo
Fisher Scientiﬁc (Huntsville, AL).
DNA Pyrosequencing Analysis
DNA pyrosequencing was performed essentially as described
previously.8 Genomic DNA was extracted from cells using
aWizard genomicDNAextraction kit (Promega,Madison,WI),
and 1 mg of the genomic DNA was bisulﬁte-modiﬁed using
a Zymo Research EZ Methylation Gold kit (Zymo Research,
Irvine, CA), according to the manufacturer’s protocol. The
bisulﬁte-modiﬁed sample DNAwas then 10-fold diluted, and 1
mL of diluted DNA was used in PCR reactions with 3 mL 10
PCR buffer, 200 mmol/L of dNTPs, 6 pmol forward primer, 6
pmol reverse primer, 3 mmol/LMgCl2, and 0.75 U HotStarTaq
DNA polymerase (205203; Qiagen, Valencia, CA) in a ﬁnal
volume of 30 mL (adjusted as necessary with double-distilled
H2O). The PCR cycling conditions were as follows: 95C for
15 minutes; 45 cycles of 95C for 30 seconds, 51C for 30
seconds, and72Cfor 30 seconds; 72Cfor 10minutes; and4C
until completion. The PSQ 96HS system (currently named
PyroMark Q96MD) (Qiagen) was used for the pyrosequencing
analysis, according to the manufacturer’s protocol. Primers
corresponding to the mouse a-SMA gene promoter region and
ﬁrst intronic region, respectively, were synthesized at EpigenDx
(Hopkinton, MA) for use in the DNA pyrosequencing.
Transfection and Reporter Gene Assay
All transient transfections of cells were performed using
FuGENE 6 reagent (Roche Applied Science, Indianapolis,
IN), according to the manufacturer’s instructions and as
described previously.8,11 Supercoiled DNA was isolated with
an endotoxin-free column kit (Qiagen). Unless otherwise
indicated, 2 mg DNA of the a-SMA promoter-luciferase
construct of interest and 100 ng plasmid pRL-SV40 control
vector (used for normalization) were cotransfected per culture
into rat lung ﬁbroblasts in serum-free DMEM. At 4 hours after
transfection, the medium was replaced with DMEM contain-
ing10%plasma-derived serumand treatedwith 4 ng/mLTGF-
b or buffer only. The cells were harvested 48 hours after
transfection, and the activity ofﬁreﬂy orRenilla luciferasewas
measured using a dual luciferase assay system (Promega). The
relative luciferase activity was calculated by normalizing
ﬁreﬂy luciferase activity to that of Renilla luciferase. Experi-
ments with each construct were repeated two to four times;
data are expressed in relative light units as means  SEM.
Electrophoretic Mobility Shift Assay
A double-stranded oligonucleotide probe corresponding to
the region between 552 and 513 in the rat a-SMA gene
promoter containing the Smad3 binding elements was
synthesized (Integrated DNA Technologies, Coralville, IA).The American Journal of Pathology - ajp.amjpathol.orgThe sequence of the sense strand was 50-TACAGACTTCA-
TTGATACTACACACAGACTCCAGACTAC-30. It was
radiolabeled with T4 polynucleotide kinase and g-[32P]ATP
and was incubated with 50 ng recombinant Smad3, as
described previously,35 or with 2 mg nuclear extract from
mouse lung ﬁbroblasts isolated from either wild-type (WT) or
PARP-1edeﬁcient knockout (KO) mice. Selected samples
were pretreated with high-speciﬁc-activity PARP-1 enzyme
(4668-100-01; Trevigen, Gaithersburg, MD) in 1 PARP
buffer (4671-096-02; Trevigen) containing the NADþ
substrate of PARP-1 before addition of the 32P-labeled probe
(20,000 to 30,000 counts/minute). The labeled probe was
incubated with the proteins in Dignam’s buffer C (20mmol/L
HEPES, pH 7.9, 0.42 mol/L NaCl, 1 mmol/L EDTA,
0.1 mmol/L EGTA, 1.0 mmol/L dithiothreitol, 100 mmol/L
sodium orthovanadate, and protease inhibitors) in a ﬁnal
volume of 15 mL for 20 minutes at room temperature. The
samples were then analyzed by electrophoresis on 4% non-
denaturing polyacrylamide gels at 150 V in 1 Tris-acetate-
EDTA buffer (40 mmol/L Tris-acetate and 1 mmol/L
EDTA, pH 8.3, at room temperature). After electrophoresis,
the gels were dried and exposed on X-ray ﬁlm for 24 hours.RNA Analysis by qPCR
Quantitative real-time PCR (qPCR) for RNA analysis to
assess gene expression was performed using an Applied
Biosystems GeneAmp 7500 sequence detection system
(Life Technologies, Foster City, CA), as described
previously.8,10,11,36 The amount of target, normalized to
endogenous reference and relative to a calibrator, is given
by 2DDCT, where CT is the cycle number at which DNA
ampliﬁcation is detected.37,38 All required primers and
probes were purchased from Applied Biosystems (Life
Technologies). Results are expressed as 2DDCT, with 18S
rRNA as the reference. The speciﬁc calibrator for each assay
was the appropriate control group mean value.Western Blot Analysis
The antiea-SMA and anti-procollagen I antibodies were
purchased from Sigma-Aldrich. All other antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Equal amounts of cell protein extracts were loaded
onto 12% SDS polyacrylamide gels and transferred onto
Hybond-P membranes (GE Healthcare, Little Chalfont, UK)
for Western blotting, as described previously.8,10,11,36 Blots
were scanned and digitized, and band intensities were
quantiﬁed using Carestream Molecular Imaging software
version 5.0.2.30 (Carestream Health, Rochester, NY).Morphological Analysis
Morphological analysis was performed on formalin-ﬁxed,
parafﬁn-embedded lung tissue sections stained with73
Hu et alMasson’s trichrome using an Accustain trichrome stain kit
(Sigma-Aldrich), according to the manufacturer’s protocol.39
Hydroxyproline Assay
As a measure of ﬁbrosis, total lung hydroxyproline content
was determined by colorimetric assay after acid hydrolysis,
as described previously.36,40 Brieﬂy, the whole lung was
removed from the animal and washed with 1 PBS. Lungs
were homogenized in 2 mL 0.5 mol/L glacial acetic acid,
dried in a centrifugal evaporator, and then baked in 6 mol/L
HCl at 110C overnight. The hydrolysates were ﬁltered and
assayed colorimetrically at 550 nm with 4-(dimethylamino)-
benzaldehyde to quantify hydroxyproline. Hydroxyproline
content was expressed on a mass basis (mg/lung).
PARP Assay
The PARP activity of human lung ﬁbroblasts was tested with
an HT colorimetric PARP/apoptosis assay kit (4684-096-K;
Trevigen), according to the manufacturer’s protocol. Brieﬂy,
cultured human lung ﬁbroblasts isolated from either control
subjects or patients with IPF34 were lysed in cell extraction
buffer prepared from the kit. The protein extracts were
then incubated with PARP substrate cocktail together
with histone-coated strip wells. To conﬁrm speciﬁcity,
3-aminobenzamide (3-AB; 10 mmol/L) was added to sample
lysates before assay. The poly(ADP-ribose) on the strip wells
was then detected by monoclonal anti-poly(ADP-ribose)
antibody and HRP-conjugated goat anti-mouse IgG anti-
body, with stringent washing for each step. TACS-Sapphire
colorimetric substrate from the kit was then added, and
PARP activity was detected by chemiluminescence.
Immunohistology
Lung tissue was removed and ﬁxed in 10% formalin,
parafﬁn-embedded, cut into 5-mm sections, and mounted
onto polylysine slides. The sections were deparafﬁnized in
xylene, rehydrated through a graded alcohol series of
methanol, and placed in a 98C water bath for 30 minutes in
citrate buffer (pH 6.0) for antigen retrieval. The sections
were quenched with 0.3% hydrogen peroxide in PBS and
incubated in normal serum for 30 minutes, to block
nonspeciﬁc binding of secondary antibodies. Endogenous
avidin or biotin binding sites were blocked by sequential
incubation for 15 minutes each with an avidin/biotin
blocking kit (Vector Laboratories, Burlingame, CA). The
sections were then incubated overnight in monoclonal
PARP-1 (Cell Signaling Technology, Danvers, MA) at 4C
at a dilution of 1:100. A Vectastain Elite ABC kit (rabbit
IgG; Vector Laboratories) was used, and the monoclonal
PARP-1 immunoreactive signal was detected with 3,30-
diaminobenzidine/nickel (Vector Labs, SK-4100) peroxi-
dase substrate. Sections were washed in PBS and the same
protocol, excluding initial tissue preparation, was repeated74using a Vectastain Elite ABC kit (mouse IgG; Vector
Laboratories). Monoclonal a-SMA antibody (Vector Labo-
ratories) at a dilution of 1:100 was applied for an incubation
time of 1 hour at room temperature. Immunoreactive signal
for the a-SMA was then detected with NovaRED (SK-4800;
Vector Laboratories) peroxidase substrate, and the ﬁnal
slides were counterstained with hematoxylin. Images were
acquired using a Leitz DMRB microscope (Leica Micro-
systems, Wetzlar, Germany) and were processed using
Photoshop CS5 software (Adobe Systems, San Jose, CA).Statistical Analysis
Statistical analysis was performed using analysis of vari-
ance followed by post hoc testing using Scheffé’s test.
Data are expressed as means  SEM, unless otherwise
indicated. Differences between means of various treatment
and control groups were assessed for statistical signiﬁcance
by analysis of variance followed by post hoc analysis
using Scheffé’s test for comparison between any two
groups. A P value of <0.05 was considered statistically
signiﬁcant.8,10,11,36,41Results
PARP-1 Activates Myofibroblast Differentiation
The importance of PARP-1 as a regulator of myoﬁbroblast
differentiation was ﬁrst evaluated by examining the effect of
the PARP-1 inhibitor 3-AB on a-SMA expression in
primary culture-derived rat lung ﬁbroblasts by qPCR.
Selected samples were also treated with TGF-b, a known
inducer of myoﬁbroblast differentiation. Treatment with 3-
AB led to dose-dependent inhibition of a-SMA gene
expression, even in cells treated with TGF-b (Figure 1A).
No appreciable cell toxicity was observed after the 3-AB
treatment at experimental doses, as determined by Trypan
Blue exclusion assay (data not shown) or by visual
inspection of the cells by phase-contrast microscopy
(Figure 1B).
To conﬁrm that this effect was speciﬁcally due to PARP-1
inhibition, PARP-1 shRNA plasmid (pGIPZ-PARP-1),
PARP-1 cDNA expression construct (pExpress1-PARP-1),
or the corresponding vector control plasmids were transfected
with FuGENE 6 reagent into rat lung ﬁbroblasts. Induced
overexpression by the PARP-1 cDNA caused a signiﬁcant
increase in a-SMA mRNA levels, even in cells treated with
TGF-b (Figure 2A). Suppression of PARP-1 expression by
the shRNA had the opposite effect on a-SMA expression.
Treatment with TGF-b induced PARP1 gene expression, and
the stimulatory effect of TGF-b on a-SMA expression was
enhanced or blunted by PARP-1 overexpression or under-
expression, respectively. Similar effects were noted when
a-SMA expression was analyzed by Western blotting,
although the effects were not as great because of theajp.amjpathol.org - The American Journal of Pathology
Figure 1 Effect of PARP-1 inhibitor on myofibroblast differentia-
tion. A: Rat lung fibroblasts were treated with TGF-b at 4 ng/mL or
buffer only (None) and the PARP-1 inhibitor 3-AB at concentrations
from 0 to 12 mmol/L for 48 hours and then were analyzed for a-SMA
mRNA by qPCR. 18S rRNA was used as the reference, and the level in
untreated control cells (without 3-AB) was used as the calibrator.
B: Representative phase-contrast images of rat lung fibroblast after
treatment for 72 hours with buffer only (top panel) or 10 mmol/L 3-AB
(bottom panel) show no appreciable cell toxicity. Data are expressed as
means  SEM. *P < 0.05 versus control. n Z 3. Original magnification,
100.
PARP-1 Activates a-SMA Gene Expressionconsiderable level of a-SMA protein already present basally
(Figure 2, BeE). In addition, there was nearly a doubling in
PARP-1 protein by the expression plasmid, whereas the
shRNA completely suppressed the TGF-b-induced doubling
of PARP-1 protein, which resulted in an approximately 50%
reduction in TGF-b-induced a-SMA expression. The PARP-
1 shRNA caused a smaller but statistically signiﬁcant
reduction of basal PARP-1 protein levels.The American Journal of Pathology - ajp.amjpathol.orgThese effects on a-SMA mRNA and protein suggest that
PARP-1 regulates a-SMA expression at the transcriptional
level. To examine this possibility, an a-SMApro-Luc
promoter construct driving a luciferase reporter gene was
transfected into ﬁbroblasts. The cells were then cotrans-
fected with the PARP-1 shRNA plasmid, PARP-1 cDNA
expression construct, or corresponding vector control plas-
mids. Consistent with the mRNA data (Figure 2), a-SMA
promoter activity was signiﬁcantly stimulated by PARP-1
overexpression (Figure 3A) but was suppressed by PARP-
1 deﬁciency induced by the shRNA (Figure 3B); neither
the absence nor the presence of TGF-b had any effect. These
ﬁndings conﬁrmed that regulation of a-SMA expression by
PARP-1 was at the transcriptional level.
PARP-1 Enhances Complex Formation with Smad3
Binding Element in the a-SMA Promoter
TGF-b induces binding of Smad3 to the Smad3 binding
consensus sequence in the a-SMA gene promoter and
enhances a-SMAgene expression.11 To test whether PARP-1
affects this binding interaction, nuclear extracts from either
WT or PARP-1edeﬁcient mouse lung ﬁbroblasts were
analyzed by electrophoretic mobility shift assay using a probe
containing the Smad3 binding consensus sequence from the
a-SMA gene promoter. Four major complexes were detect-
able with nuclear extracts from WT and PARP-1edeﬁcient
mouse lung ﬁbroblasts (Figure 4A). Band intensities were
weaker in the samples from deﬁcient mice; however, when
these samples were pretreated with PARP-1, band intensities
were enhanced almost to the WT level. Thus, PARP-1
appears to be essential for optimal complex formation with
this probe. Incubation of the probe with recombinant Smad3
resulted in a single complex (Figure 4B), and pretreatment
with PARP-1 did not cause a noticeable change in band
intensity, suggesting that additional factors in the nuclear
extract are necessary for PARP-1emediated enhancement of
complex formation.
PARP-1 Deficiency Induces DNA Hypermethylation of
a-SMA Gene CpG Islands
Previous studies have demonstrated the presence of CpG
islands in the rat a-SMA gene (GenBank accession no.
NC_005100.3 and no. JX430794.1), as well as showing that
methylation suppressed gene expression.8 Similar CpG
islands were identiﬁed in mouse Acta2 by sequence analysis
(Supplemental Figure S1). Given that PARP-1 and Dnmt1
are associated in vivo and that ADP-ribose polymers
modulate Dnmt1 activity,32 the effect of PARP-1 on the
methylation of the a-SMA gene was examined. Genomic
DNA from either PARP-1edeﬁcient (KO) or WT murine
lung ﬁbroblasts was isolated and analyzed for methylation
status of the identiﬁed a-SMA gene CpG sites in the
promoter and intronic regions by DNA pyrosequencing, as
described previously.8 The analysis indicated a greater than75
Figure 2 PARP-1 regulation of a-SMA expression. A: PARP-1 cDNA plasmid (pCMV-sport6-PARP-1), PARP-1 shRNA expression construct (pGIPZ-
shPARP-1), or their corresponding empty vector control (Vector only) were transfected into rat lung fibroblasts. The cells were treated with buffer only (None)
or with 4 ng/mL TGF-b and then were analyzed for a-SMA mRNA by qPCR analysis 12 hours after transfection. 18S rRNA was used as reference, and the level in
untreated cells transfected with vector only was used as the calibrator. BeE: Cells were analyzed for protein by Western blot analysis for a-SMA, PARP-1, and
GAPDH 72 hours after transfection. Protein extracts from cells transfected with PARP-1 cDNA or the corresponding vector (B and C) or transfected with
PARP-1 shRNA or the corresponding vector (D and E) were analyzed by Western blot analysis for a-SMA and PARP-1 expression. The membrane was reblotted
with anti-GAPDH antibody for loading control. Relative density of the bands from three independent experiments was quantified. Data are expressed as means
 SEM (A, C, and E), normalized to the density of corresponding GAPDH bands (C and E). n Z 3. *P < 0.05 versus control.
Hu et altwofold increase in DNA methylation status of 8/9 CpG
sites identiﬁed in the a-SMA gene (Figure 5). In the
majority of these sites, especially in the intronic regions, the
increase was more than fourfold. These ﬁndings conﬁrm the
importance of PARP-1 in regulating a-SMA gene methyl-
ation, which is known to profoundly affect gene expression.
Thus, in addition to regulation at the transcriptional level,
PARP-1 may regulate myoﬁbroblast differentiation at least
in part through this epigenetic mechanism.
In Vivo Effects of PARP-1 Deficiency
The myoﬁbroblast arises de novo at sites of tissue injury
undergoing repair to play a key role in the subsequent
ﬁbrotic phase. This process is characterized by induction of
a-SMA expression, which was demonstrated in vitro to be
regulated in part by PARP-1 (Figures 1e5). To determine
whether these in vitro effects of PARP-1 on myoﬁbroblast
differentiation have any in vivo or pathophysiological
signiﬁcance, we examined the effects of PARP-1 deﬁciency
on myoﬁbroblast differentiation in a model of lung injury
and ﬁbrosis using PARP-1 KO mice. In this model, endo-
tracheal injection of bleomycin into WT mice causes acute76lung injury, followed by signiﬁcant ﬁbrosis associated with
induction of myoﬁbroblast differentiation (as monitored by
a-SMA expression).3,42 In the present study, the expected
ﬁbrosis (as measured by lung hydroxyproline content) was
observed in WT mice; in KO mice, ﬁbrosis was signiﬁcantly
reduced, by >50% (Figure 6A). This diminished ﬁbrosis in
response to PARP-1 deﬁciency was accompanied by similar
reductions in lung a-SMA and type I collagen mRNA levels
in KO mice (Figure 6B). The signiﬁcantly diminished
mRNAs for both a-SMA and type I collagen in the KO mice
were also reﬂected in their protein levels (as analyzed by
Western blotting) (Figure 6C). Finally, histopathological
evaluation conﬁrmed the reduction in ﬁbrosis in the KO
mice (Figure 7). Although lungs from WT mice showed the
typical marked distortion of alveolar architecture, matrix
deposition, and interstitial ﬁbrosis, those from KO mice
were largely spared, and ﬁbrotic lesions were much smaller
and less extensive.
To determine whether the reduced ﬁbrotic response in
PARP-1edeﬁcient mice was related to suppression of myo-
ﬁbroblast differentiation, a-SMA expression in mouse lung
ﬁbroblasts was analyzed by Western blotting. The reduced
collagen expression in PARP-1edeﬁcient mouse lungajp.amjpathol.org - The American Journal of Pathology
Figure 3 PARP-1 regulation of a-SMA gene transcription. PARP-1 cDNA
plasmid, PARP-1 shRNA expression construct, or empty vector (Vector
only) were transfected together with the WT rat a-SMA promoter-luciferase
fusion plasmid, pGL3-a-SMApro-Luc, into rat lung fibroblasts. Cells were
treated with buffer only (None) or TGF-b and analyzed for a-SMA promoter
activity. The effects of PARP-1 cDNA (A) or PARP-1 shRNA (B) on a-SMA
promoter activity were determined in terms of luciferase activities. Data
are expressed as means  SEM, normalized to the respective Renilla
luciferase control activity (to correct for transfection efficiency). n Z 3.
*P < 0.05 versus control.
Figure 4 Binding of Smad3 to Smad3 binding element in the rat a-SMA
gene. Double-stranded oligo DNA primers containing the Smad3 binding
element in the rat a-SMA gene were synthesized and labeled with 32P for use
in an electrophoretic mobility shift assay. Nuclear extracts (2 mg) from
PARP-1edeficient (KO) or WT mouse lung fibroblasts (A) or 50 ng of
recombinant Smad3 (B) were incubated with the 32P-labeled probe and then
analyzed by gel electrophoresis. Nuclear extracts from PARP-1 KO cells (A) or
purified Smad3 (B) were pretreated with PARP-1 enzyme without or with the
PARP-1 cofactor (NADþ), or with buffer only, before addition of the probe.
Samples with the PARP-1 treatment only (without nuclear extract or Smad3)
were also incubated with the 32P-labeled probe, as controls. To document
binding specificity, excess cold probe (100) was added to the reaction
mixture. The protein-DNA complexes formed by nuclear extract (A) or Smad3
(B) with the labeled oligo DNA were indicated by arrows.
PARP-1 Activates a-SMA Gene Expressionﬁbroblasts correlated with a reduction in a-SMA expression
in lung, which was only slightly stimulated by bleomycin
treatment in PARP-1edeﬁcient ﬁbroblasts (in contrast to the
robust response in WT cells) (Figure 8). Thus, PARP-1
deﬁciency had signiﬁcant in vivo consequences, manifested
by reduced myoﬁbroblast differentiation and pulmonary
ﬁbrosis as deﬁned biochemically, by matrix gene expression,
and histopathologically.
To further examine whether these ﬁndings in a rodent
model could also be relevant to human disease, PARP-1
expression and PARP activity were analyzed in lung
ﬁbroblasts isolated from control subjects or from patients
with IPF. The levels of PARP-1 and a-SMA mRNAs in
cells from IPF patients were signiﬁcantly higher than those
in the control cells (Figure 9A), conﬁrming the association
between PARP-1 and myoﬁbroblast differentiation. The
elevated expression of PARP-1 in cells from IPF patientsThe American Journal of Pathology - ajp.amjpathol.org 77
Figure 5 Methylation at individual CpG sites. Genomic DNA isolated
from either WT (parp1þ/þ) or PARP-1-deficient (parp1/) murine lung
fibroblasts was analyzed for DNA methylation by DNA pyrosequencing with
primers specific for the mouse a-SMA gene. The CpG sites are numbered
relative to the transcription start site in the mouse a-SMA gene. Data are
expressed as means  SEM. n Z 3. *P < 0.05 versus WT control.
Hu et alwas reﬂected in the level of PARP activity in ﬁbroblasts
isolated from IPF patients, which was more than threefold
higher than that in ﬁbroblasts isolated from control subjects
(Figure 9B). The speciﬁcity of the assay was conﬁrmed by
susceptibility to inhibition by 3-AB.
To conﬁrm induction and localization of PARP-1
expression in vivo in IPF, lung tissue sections from control
and IPF patients were immunostained with antibodies to78PARP-1 and a-SMA. This approach revealed induction of
PARP-1 nuclear staining in cells within ﬁbroblastic foci in
IPF lung sections (Figure 9C). The PARP-1 nuclear staining
colocalized in cells with cytoplasmic a-SMA staining,
consistent with induction of PARP-1 in myoﬁbroblasts in
these ﬁbroblastic foci. Control lung sections showed normal
alveolar architecture without detectable staining for PARP-1,
whereas a-SMA staining was detectable in smooth muscle
cells of the vasculature and airways (Figure 9C). These
ﬁndings conﬁrmed the in vitro studies using isolated lung
ﬁbroblasts, suggesting the potential importance of PARP-1 in
genesis of the myoﬁbroblast in IPF.
Discussion
PARP-1 is widely involved in the regulation of DNA repair,
DNA replication, modulation of chromatin structure, and
apoptosis.43 All of these processes are of potential importance
in development and cell differentiation. Myoﬁbroblasts
are also important in development, cancer, tissue repair,
remodeling, and ﬁbrosis.1e3,7,9 Myoﬁbroblasts commonly
arise from tissue ﬁbroblasts, although other precursor
cells have also been identiﬁed.7 Differentiation from these
precursor cells is manifested by induction of a-SMA
expression and its incorporation into stress ﬁbers.3,7,9
Extensive studies have revealed a complex differentiation
mechanism involving diverse signaling pathways, transcrip-
tion, and epigenetic factors.1,3,7e11 Although understanding
of this mechanism remains incomplete, it is of considerable
interest, given the importance of the myoﬁbroblast inFigure 6 In vivo effects of PARP-1 deficiency.
PARP-1 KO mice and their WT controls were
treated with saline (sal) or bleomycin (blm) to
induce lung injury and fibrosis. The lungs were
then harvested for analysis of fibrosis (total
hydroxyproline content) (A) and for myofibroblast
differentiation (a-SMA mRNA and protein) and
matrix synthesis (type I collagen mRNA and
protein) (BeD). A: Collagen deposition was
evaluated by hydroxyproline analysis 21 days after
bleomycin treatment. B: Lung a-SMA and a1(I)
procollagen mRNAs were detected by qPCR using
the 2DDCT method. 18S rRNA was used as refer-
ence, and the level in saline-treated WT mice was
used as the calibrator. C: Lung a-SMA and a1(I)
procollagen proteins were analyzed by Western
blotting. Each lane represents a sample from
a single animal. GAPDH was used as a loading
control, after stripping of the membrane. D:
Relative density of the bands was quantified from
three independent experiments, normalized to the
density of corresponding GAPDH bands. Data
are expressed as means  SEM. nZ 5 (A); nZ 3
(BeD). *P < 0.05.
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Figure 7 Effect of PARP-1 deficiency on histopathology. PARP-1e
deficient and WT mice were treated with bleomycin to induce lung injury
or with saline as a control. On day 21 after treatment, lung tissue sections
were obtained and stained with Masson’s trichrome. Representative sections
from WT mice treated with saline (A and E) or bleomycin (B and F) and from
PARP-1 KO mice treated with saline (C and G) or bleomycin (D and H) show
reduced fibrosis in the KO mice. Original magnification,100 (AeD);400
(EeH).
Figure 8 Effect of PARP-1 deficiency on lung fibroblasts. A: Lung fibro-
blasts isolated from either saline- or bleomycin-treated WT or PARP-
1edeficient mice (7 days after bleomycin treatment) were analyzed for a-SMA
and a1(I) procollagen proteins by Western blotting. Each lane represents
a sample from a single animal. GAPDH was used as a loading control, after
stripping of the membrane. B: Relative density of the bands was quantified
from three independent experiments, normalized to the density of corre-
spondingGAPDHbands. Data are expressed asmeans SEM.nZ3. *P< 0.05.
PARP-1 Activates a-SMA Gene Expressiondevelopment, tissue ﬁbrosis, and cancer.1e4,6,7 In the present
study, we hypothesized that PARP-1 may regulate a-SMA
gene expression.
This hypothesis was ﬁrst tested in vitro, to see whether
inhibition of PARP activity could affect myoﬁbroblast
differentiation in isolated rodent lung ﬁbroblasts. The
inhibitor 3-AB had a signiﬁcant inhibitory effect on a-SMA
expression, and thus also on myoﬁbroblast differentiation.
This effect was conﬁrmed to be due to PARP-1, because
induced overexpression using a PARP-1 expression plasmid
stimulated a-SMA expression but suppression by trans-
fection of PARP-1 shRNA caused a signiﬁcant reduction in
a-SMA expression. Use of an a-SMA promoter-reporter
gene construct revealed that these effects on both ﬁbro-
blast PARP-1 mRNA and protein levels were due to regu-
lation at the transcriptional level. This is consistent with
previous reports that poly(ADP-ribose) can modulate gene
transcription by interfering directly with transcription factors
and cofactors. For example, PARP-1 interacts with andThe American Journal of Pathology - ajp.amjpathol.orgstimulates NF-kB in the absence of poly(ADP-ribose) syn-
thesis.44e46 NF-kB is a transcription factor with regulatory
activity on myoﬁbroblast differentiation.47e49 PARP-1 also
binds speciﬁcally to both TEF-1 and the ﬂanking sequences
of the MCAT1 element.50 PARP-1 coimmunoprecipitates
with TEF-1 from muscle nuclear extracts and can ribosylate
TEF-1 in vitro (ADP ribosylation).50 Inhibition of PARP
enzymatic activity represses expression of an MCAT1-
dependent promoter.50 Two MCAT elements are also found
in the a-SMA gene promoter.51,52 Interestingly, their inter-
action with TEF-1 regulates the transcription of the a-SMA
gene in a cell-speciﬁc manner.51,52 Mutations of MCAT
elements selectively abolish the a-SMA transcriptional
activity in myoﬁbroblasts within granulation tissue of skin
wounds.52
Another key regulator of a-SMA gene transcription is
Smad3, a key factor of the TGF-b signaling pathway. Elec-
trophoretic mobility shift assays revealed that complex
formation with a probe containing the Smad3 binding
consensus sequence or element (SBE) was reduced when
PARP-1 was deﬁcient in the nuclear extract sample. This
reduction was reversed by preincubation of the nuclear
extract with PARP-1, thus indicating that PARP-1 was
essential for optimal complex formation with the SBE.
However, PARP-1 pretreatment of recombinant Smad3 did
not appear to affect its binding to the SBE signiﬁcantly.
A possible explanation is that modiﬁcation of Smad3 by
PARP-1 requires phosphorylation of Smad3, which would79
Figure 9 PARP-1 expression is up-regulated in human fibrotic lung
fibroblasts and fibroblastic foci. A: Lung fibroblasts from IPF patients or
from control subjects (CON) without pulmonary fibrosis were analyzed
for PARP-1 and a-SMA mRNAs by qPCR. 18S rRNA was used as the
reference, and the level in cells from control subjects (CON) was used as
the calibrator. B: Lung fibroblasts from IPF patients or from control
subjects (CON) without pulmonary fibrosis were analyzed for PARP
activity in the presence or absence of 3-AB (10 mmol/L). C: Lung tissue
sections from two IPF patients (top panels) and a control subject
(bottom left panel) were stained with antiePARP-1 (nickel; black
stain) and a-SMA (NovaRED; red stain) antibodies. The IPF lung sections
show fibroblastic foci with cells positively staining for both nuclear
PARP-1 and cytoplasmic a-SMA (arrows). The control lung section shows
no detectable staining for PARP-1, but shows positive staining for
a-SMA in airway and vascular smooth muscle cells. Nonimmune IgG
control (bottom right panel) staining of an IPF lung section confirmed
specificity of staining. Data are expressed as means  SEM. n Z 3 (A);
n Z 5 (B). *P < 0.05 versus control. Scale bar Z 50 mm. Original
magnification, 400.
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80not occur in the absence of the requisite kinase in the setting
of the experiment using the recombinant Smad3. This
possibility was suggested in a study in smooth muscle cells,
in which a similar effect of PARP-1 on Smad3 modiﬁcation
and binding to the SBE occurred only with phosphorylated
Smad3.29 In contrast to the recombinant Smad3 experiment,
the nuclear extract samples likely contained phosphorylated
Smad3, because of endogenous TGF-b signaling11; thus,
PARP-1 should be able to interact with this phosphorylated
form of Smad3. Alternatively, other factors present in the
nuclear extract may be necessary for PARP-1 interaction or
regulation of Smad3 binding to the SBE. The modiﬁcation of
Smad3 by PARP-1 and its functional effects appear to be cell
speciﬁc.28,29 Thus, in smooth muscle cells and ﬁbroblasts in
the present study, PARP-1 was found to enhance Smad3
binding and activate its target gene, which is in contrast to the
attenuation by PARP-1 of the TGF-b signaling in HaCaT
keratinocytes by blunting Smad3 binding to the SBE.28 In the
latter study, inhibition of epithelial-mesenchymal transition
by PARP-1 was also noted; however, this ﬁnding is contra-
dicted by another study showing that PARP-1 is essential for
epithelial-mesenchymal transition.53 Nevertheless, it appears
that, at least in mesenchymal cells capable of a-SMA
expression, PARP-1 functions as an activator of a-SMA gene
transcription.
In addition to regulation of transcription factors, PARP-1 is
involved in modulation of chromatin structure and epigenetic
control.32,54e59 PARylation of histone by PARP-1 causes
relaxation of chromatin superstructure54e56 and dissociation
of histone-DNA complexes,57e59 which increases the acces-
sibility of the trans-acting factors and RNA polymerase to
DNA to enable gene transcription.60e62 Moreover PARP-1
associates with DNA methyltransferases 1 and modulates its
activity.32 Recent reports suggest that DNAmethylation may
play signiﬁcant roles in pulmonary ﬁbrosis.8,36,63e65 The
present results indicate that PARP-1 deﬁciency in cells from
PARP-1KOmice resulted in hypermethylation of thea-SMA
gene, as shown by quantitative DNA pyrosequencing, and
thus provide direct evidence for the ﬁrst time of the impor-
tance of PARP-1 in the regulation of DNA methylation.
Increased DNA methylation due to overexpression of
DNA methyltransferase leads to suppression of a-SMA gene
expression, whereas inhibition of DNA methyltransferase
activity or knockdown of DNA methyltransferase causes
signiﬁcant induction of a-SMA in ﬁbroblasts.8,36 In the
present study hypermethylation of the a-SMA gene was
observed in PARP-1edeﬁcient cells, which correlated with
signiﬁcantly reduced a-SMA gene expression. Thus, our data
suggest that PARP-1 has a signiﬁcant role in regulation of
myoﬁbroblast differentiation at the transcriptional and
epigenetic levels. It remains unclear, however, whether the
transcriptional regulation is via direct mechanisms, in which
PARP-1 itself is interfering with the binding or activity of
transcription factors that regulate the a-SMA promoter,
and/or via more distant mechanisms involving upstream
signaling pathways targeting both the a-SMA gene and otherajp.amjpathol.org - The American Journal of Pathology
PARP-1 Activates a-SMA Gene Expressiondifferentiation-relevant genes. Similar uncertainty applies
also to the epigenetic mechanism, because the present study
could not exclude effects of DNA methylation on
differentiation-relevant genes other than the a-SMA gene.
Moreover, the effect of PARP-1 deﬁciency on DNA meth-
ylation may be due to a balance favoring PARG, rather than
to an absence of PARP-1 per se. Nevertheless, taken together,
these in vitro ﬁndings indicate the importance of PARP-1 in
regulation of a-SMA gene expression and thus myoﬁbroblast
differentiation.
To determine whether these in vitro ﬁndings are of in vivo
signiﬁcance, the effects of PARP-1 deﬁciency were investi-
gated in an animal model in which myoﬁbroblast differenti-
ation was considered to be an important pathogenetic factor.
The PARP-1 KOmice were studied in a model of lung injury
and ﬁbrosis induced by endotracheal injection of bleomycin.
Compared with WT control mice, these KO mice exhibited
a signiﬁcantly reduced response to bleomycin, with
suppression of lung ﬁbrosis and expression of a-SMA and
type I collagen genes indicative of reduced myoﬁbroblast
differentiation. This ﬁnding was conﬁrmed by analysis of
lung ﬁbroblasts isolated from these mice. Moreover, ﬁbro-
blasts isolated from ﬁbrotic human lung exhibited signiﬁ-
cantly higher levels of PARP-1 expression and PARP
activity, which correlated with higher levels of a-SMA
expression. This induction of PARP-1 in myoﬁbroblasts was
also observed in IPF lung tissue sections, providing further
evidence for the in vivo relevance to pathogenesis of IPF.
Thus, in addition to demonstrating the regulatory signiﬁcance
of PARP-1 on myoﬁbroblast differentiation and ﬁbrosis
in vivo, these latter ﬁndings also suggest potential relevance to
human ﬁbrotic lung disease. Because PARP-1 also plays
critical roles in other oxidative stress-related lung diseases,
including asbestosis, silicosis, acute respiratory distress
syndrome, and ischemia-reperfusion injury,31,66e68 the
present ﬁndings may help to elucidate the regulatory mech-
anism or mechanisms in those diseases, as well as in IPF.
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